Results 101 to 110 of about 12,023,937 (197)
Follistatin is an inhibitor of TGF-β superfamily ligands that repress skeletal muscle growth and promote muscle wasting. Accordingly, follistatin has emerged as a potential therapeutic to ameliorate the deleterious effects of muscle atrophy.
A Hagg (13448925) +8 more
core
Advance in the study of inhibin, activin and follistatin production in pregnant women
This review summarizes the new information on the studies of inhibin, activin, and follistatin production in the placenta during human pregnancy. Inhibin and activin exert suppressive and stimulatory effects, respectively, on the release of FSH in the ...
Qu, Jianping +3 more
core +1 more source
Myostatin, a member of the transforming growth factor (TGF)-β superfamily, plays a potent inhibitory role in regulating skeletal muscle mass. Inhibition of myostatin by gene disruption, transgenic (Tg) expression of myostatin propeptide, or injection of ...
Masahiro Kokubo +4 more
core +1 more source
Transforming growth factor beta family ligands are neutralized by a number of structurally divergent antagonists. Follistatin-type antagonists, which include splice variants of follistatin (FS288 and FS315) and follistatin-like 3 (FSTL3), have high ...
Schneyer, Alan
core +1 more source
Low cutaneous follistatin expression is associated with striae gravidarum: A pilot study of the TGF-β/BMP signaling pathway. [PDF]
Tian T, Wang H, Li Y.
europepmc +1 more source
Grip strength as a systems biomarker of aging: neuromuscular junction constraints and biomarker decoupling in gene therapy. [PDF]
Sewell PE, Jensen C.
europepmc +1 more source
Secreted Frizzled-Related Protein 2 (SFRP2) Induces Follistatin-Like 1 (FSTL1) to Regulate Dihydrotestosterone (DHT)-Induced Dermal Papilla Cell Mitochondrial Dysfunction and Senescence. [PDF]
Huang Y +7 more
europepmc +1 more source
Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathies. [PDF]
Vernerová L +15 more
europepmc +1 more source

